Bedrijfsoverzicht
Atara Biotherapeutics, Inc. is a biotechnology entity dedicated to the development of transformative therapies designed for patients suffering from cancer and autoimmune diseases both within the United States and in international markets. The company operates within the healthcare sector, specifically focusing on the biotechnology industry, which implies a high-risk, high-reward environment driven by significant research and development expenditures and regulatory milestones. Currently, the organization employs a lean workforce of 14 individuals, reflecting an early-stage operational scale typical for clinical development firms. The company's market capitalization stands at $38.03M, with reported trailing twelve-month revenue of $120.77M, figures that suggest a valuation structure where the market price significantly diverges from the stated revenue, potentially indicating accounting adjustments, one-time gains, or specific valuation methodologies not standard for public operating companies.
Financiële gezondheid
The company reports a trailing twelve-month revenue of $120.77M alongside a net income of $32.69M, creating a scenario where the profit margin is calculated at 27.1% while the operating margin shows a substantial deficit of -339.6%. This distinct gap between revenue and net income, coupled with an operating margin that is negative multiple times the revenue, reveals a cost structure where non-operating income or significant one-time credits are contributing heavily to the bottom line rather than core operational efficiency. The firm currently holds $8.48M in cash against $10.38M in debt, resulting in a free cash flow of -$47,677,624, which indicates a heavy reliance on external capital or non-cash accounting adjustments to sustain operations without generating internal cash reserves. The balance sheet exhibits a debt-to-equity ratio listed as N/A, suggesting that the equity structure may be complex or that the company is capitalizing significant intangible assets common in biotech, while the current ratio of 0.82 signals potential short-term liquidity constraints where current liabilities exceed current assets. Despite the operating challenges, the return on assets stands at 47.8%, a metric that is unusually high for a company with negative operating margins and suggests that asset utilization is being driven by specific accounting entries rather than operational profitability. Return on equity is listed as N/A, preventing a standard assessment of how effectively management is utilizing shareholder equity to generate returns.
Waarderingsbeoordeling
The valuation metrics present a complex picture with a trailing P/E ratio of 1.81 and a forward P/E of 5.74, implying that the market expects earnings to increase significantly in the future to justify the higher multiple, though the low trailing multiple suggests the current earnings base is supported by non-recurring items. The price-to-book ratio is -0.88, a negative figure that indicates the company's market value is below its book value or that the book value includes significant intangible assets that are not captured in the standard market pricing, removing any traditional market premium over book value. Alternative valuation metrics include a price-to-sales ratio of 0.31 and an EV/EBITDA of 0.77, which suggests the company is trading at a fraction of its sales and earnings power relative to typical peers, often seen in pre-revenue or clinical-stage companies. Regarding price volatility, the stock has a 52-week high of $19.14 and a 52-week low of $3.92, with the current implied price context being heavily influenced by the negative beta of -0.33, which indicates an inverse correlation to the broader market where the stock tends to move in the opposite direction of the market index. The beta value of -0.33 suggests that for every 1% move in the broader market, this stock theoretically moves 0.33% in the opposite direction, providing a distinct risk profile for a portfolio seeking negative correlation assets.
Growth & Income
The growth profile is characterized by a revenue decline of -95.1% year-over-year and earnings growth listed as N/A, indicating that the traditional metric of expanding top-line sales is not currently applicable to this specific reporting period or that the revenue figures reflect a change in accounting recognition or one-time events rather than organic business expansion. Since the company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it follows the standard biotechnology model of reinvesting any generated earnings back into research, development, and clinical trials rather than distributing income to shareholders. The absence of a payout ratio means there is no obligation to distribute cash, allowing the company to retain all available resources for its Phase 3 clinical trials and development programs despite the negative free cash flow. Overall, the company's profile is defined by a lack of current income generation through dividends and significant revenue contraction metrics, focusing entirely on long-term product development rather than immediate financial growth or shareholder yield.